Seer Proteograph Platform with ID-free AI Profiles 5,500 Samples, Yields 14,000 Proteins
SEER•Seer and Korea University presented preliminary ASMS 2026 data showing their Proteograph Product Suite with ID-free AI analyzed 5,500 plasma samples across ten cancers, detecting 14,000 protein groups per sample. This collaboration will scale to over 20,000 plasma samples to support future multi-cancer screening studies.
1. Presentation at ASMS 2026
Seer and Korea University showcased preliminary data at the annual ASMS conference, highlighting the potential of AI-driven plasma proteomics for multi-cancer screening. The joint team demonstrated feasibility by analyzing over 5,500 plasma samples spanning ten major cancer types using the Proteograph Product Suite integrated with an ID-free AI framework.
2. Proteomic Coverage and ID-free AI
The analysis achieved an average detection of more than 14,000 protein groups per sample, underscoring the platform’s depth and reproducibility at population scale. The ID-free AI approach allowed researchers to leverage substantial portions of mass spectrometry data that traditional identification methods overlook, uncovering novel biological patterns.
3. Expansion to 20,000 Samples
Building on these early results, the collaboration is set to expand its scope to over 20,000 clinical plasma samples across Korea’s highest-incidence cancers. This larger dataset aims to create a comprehensive proteomic reference resource to evaluate and refine future multi-cancer screening strategies.
